M
Michihisa Moriguchi
Researcher at Kyoto Prefectural University of Medicine
Publications - 14
Citations - 432
Michihisa Moriguchi is an academic researcher from Kyoto Prefectural University of Medicine. The author has contributed to research in topics: Sorafenib & Hepatocellular carcinoma. The author has an hindex of 9, co-authored 14 publications receiving 321 citations.
Papers
More filters
Journal ArticleDOI
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
Thomas Yau,Chiun Hsu,Tae You Kim,Su Pin Choo,Yoon-Koo Kang,Ming-Mo Hou,Kazushi Numata,Winnie Yeo,Akhil Chopra,Masafumi Ikeda,Ryoko Kuromatsu,Michihisa Moriguchi,Yee Chao,Huanyu Zhao,Jeffrey Anderson,Christine Dela Cruz,Masatoshi Kudo +16 more
TL;DR: The CheckMate 040 study as mentioned in this paper evaluated the safety and efficacy of nivolumab in patients with advanced hepatocellular carcinoma who were refractory to previous sorafenib treatment or chemotherapy.
Journal ArticleDOI
The copper chelator trientine has an antiangiogenic effect against hepatocellular carcinoma, possibly through inhibition of interleukin-8 production.
Michihisa Moriguchi,Tomoki Nakajima,Hiroyuki Kimura,Tadashi Watanabe,Hidetaka Takashima,Yasuhide Mitsumoto,Tatsuo Katagishi,Takeshi Okanoue,Keizo Kagawa +8 more
TL;DR: The chelating effect of trientine prevented copper from functioning as a cofactor in angiogenesis, which resulted in reduced IL‐8 production from HuH‐7 cells.
Journal ArticleDOI
Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma.
Aya Takahashi,Michihisa Moriguchi,Yuya Seko,Hiroki Ishikawa,Takaharu Yo,Hiroyuki Kimura,Hideki Fujii,Toshihide Shima,Yasuhide Mitsumoto,Hiroshi Ishiba,Hidetaka Takashima,Yasuyuki Nagao,Masayasu Jo,Masahiro Arai,Tasuku Hara,Akira Okajima,Akira Muramatsu,Atsuhiro Morita,Naomi Yoshinami,Tomoki Nakajima,Hironori Mitsuyoshi,Atsushi Umemura,Taichiro Nishikawa,Kanji Yamaguchi,Yoshito Itoh +24 more
TL;DR: It is suggested that maintaining an RDI ≥75% during the initial 8 weeks of lenvatinib treatment has a favorable impact on response, compared with patients with 8W-RDI <75%.
Journal ArticleDOI
Sorafenib versus Hepatic Arterial Infusion Chemotherapy as Initial Treatment for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombosis.
Michihisa Moriguchi,Takeshi Aramaki,Hideyuki Nishiofuku,Rui Sato,Koiku Asakura,Kanji Yamaguchi,Toshihiro Tanaka,Masahiro Endo,Yoshito Itoh +8 more
TL;DR: For the treatment of HCC with Vp3/Vp4, it is desirable to initially use LFP and then immediately change to sorafenib if no response is obtained.
Journal ArticleDOI
Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma.
TL;DR: The therapeutic effect of sorafenib is limited, so development of a more effective treatment method and second-line treatments is needed, and trials with immune-checkpoint inhibitors, which have an entirely different anti-tumor mechanism from that of molecular targeted drugs or cytotoxic drugs, have recently begun.